The instant invention involves the use of a combination of preparatory steps
in conjunction with mass spectroscopy and time-of-flight detection procedures to
maximize the diversity of biopolymers which are verifiable within a particular
sample. The cohort of biopolymers verified within such a sample is then viewed
with reference to their ability to evidence at least particular disease state;
thereby enabling a diagnostician to gain the ability to characterize either the
presence or the absence of at least one disease state relative to recognition of
the presence and/or the absence of the biopolymer, predict disease risk assessment,
and develop therapeutic avenues against the disease.
